Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1770064 | 0.84 | NPC1 (0.49) | HSD11B1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL1770073 | 0.80 | NPC1 (0.46) | HSD11B1ALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL1770040 | 0.73 | HSD11B1 (1.00) | HSD11B1ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL1770354 | 0.72 | MEN1 (0.42) | HSD11B1ALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL25197939 | 0.72 | ALDH1A1 (0.44) | HSD11B1ALDH1A1TSHR | |
| SCHEMBL3323577 | 0.71 | RAB9A (0.43) | HSD11B1ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL10349958 | 0.71 | ALDH1A1 (0.42) | HSD11B1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL1769896 | 0.71 | GRM5 (0.47) | HSD11B1ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL1770472 | 0.71 | HSD11B1 (0.56) | HSD11B1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL1769893 | 0.70 | CYP17A1 (0.48) | HSD11B1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885ALDH1A1 307/4885NPC1 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.